How the 3q29 genetic deletion affects thinking, behavior, and mental health
The schizophrenia-associated 3q29 deletion: genetic architecture of behavioral phenotypes
The project looks at how a rare genetic deletion called 3q29 changes thinking, behavior, and risk for conditions like schizophrenia, autism, ADHD, and anxiety in people who have it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11242045 on NIH RePORTER |
What this research studies
If you join, researchers will use a remote testing battery you can complete from home to measure thinking, social skills, mood, and motor tasks. They plan to include about 200 people with the 3q29 deletion and will also collect information from biological parents to understand family background. The team will compare each person's overall genetic background and sex with their symptoms to see what changes risk for psychosis, cognitive challenges, and social or attention problems. The remote approach is designed to remove travel barriers and make participation easier for families.
Who could benefit from this research
Good fit: People with a confirmed 3q29 deletion, and willing biological parents for family comparison, are the ideal candidates for this project.
Not a fit: People without the 3q29 deletion, or anyone looking for an immediate treatment or cure, are unlikely to receive direct medical benefit from participating.
Why it matters
Potential benefit: This work could help identify who with the 3q29 deletion is most likely to develop schizophrenia or other neurodevelopmental problems so they can get earlier monitoring and support.
How similar studies have performed: Prior research has already linked 3q29 deletion to much higher schizophrenia risk and developmental issues, but enrolling 200 people with remote phenotyping is a newer, larger-scale approach.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Mulle, Jennifer Gladys — Rutgers Biomedical and Health Sciences
- Study coordinator: Mulle, Jennifer Gladys
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.